P-wave dispersion. Prediction of atrial fibrillation in the hypertensive patient
Keywords:
Pwave dispersion, hypertension, atrial fibrillationDownloads
References
1. Olaz F, Berjón J. Valoración cardiológica del paciente hipertenso. Anales San Navarra. 1998;21(Supl. 1):39-53.
2. Dilaveris P, Stefanadis Ch. P Wave Dispersion: A Valuable Non-Invasive Marker of Vulnerability to Atrial Fibrillation. Proceedings of the 2nd ISHNE atrial fibrillation worldwide internet symposium; 2007 April 1-30.London: St. Jude Medical; 2007. Disponible en: http://www.af-symposium.org/2007/lectures.php
3. Cagirci G, Cay S, Karakurt O, Eryasar N, Acikel S, Dogan M, et al. P-wave dispersion increases in prehypertension. Blood Press. 2009;18(1-2):51-4.
4. Baguet JP, Erdine S, Mallion JM. Hypertensión and arrhythmia. European Society of Hypertension Scientific Newsletter: Update on hypertension management. ESH [Internet]. 2005 [citado 22 Mar 2010];6(24):[aprox. 4 p.]. Disponible en: www.ehy.ee/.../2005%20HYPERTENSION%20AND%20ARRHYTMIA.pdf
5. Rubart M, Zipes DP. Génesis de las arritmias cardiacas: consideraciones electrofisiológicas. En: Braunwald E, Zipes DP, Libby P. Braunwald´s Cardiología “El libro” de medicina cardiovascular vol 1. 6ta ed. Madrid: Marbán Libros; 2004. p. 810-1.
6. Zecchi P, Russo AD, Pelargonio G, Sanna T, Porto I, Messano L, et al. Clinical electrocardiographic and electrophysiological predictors of atrial fibrillation development in different cardiac substrates. Ann Ist Super Sanita. 2001;37(3):443-8.
7. Necati Dagli N, Karaca I, Yavuzkir M, Balin M, Arslan N. Are maximum P wave duration and P wave dispersion a marker of target organ damage in the hypertensive population? Clin Res Cardiol. 2008;97(2):98-104.
8. Köse S, Aytemir K, Sade E, Can I, Özer N, Amasyali B, et al. Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersión. Clin Cardiol. 2006;26(9):431-4.
9. Celik T, Iyisoy A, Kursaklioglu H, Yilmaz MI, Kose S, Kilic S, et al. Telmisartan has a much greater lowering effect on PWD and P maximum values than ramipril. Clin Cardiol. 2005;28(6):298-302.
10. Zanchetti A. Prevalencia de hipertensión de alto y muy alto riesgo en las consultas de atención primaria y unidades de hipertensión en España [CD-ROM]. 10ma ed. Reunión Nacional SEH-LELHA. Barcelona: Elsevier; 2005.
11. Lombardi F. Inhibidores ECA y FA. Tercer simposio internacional de fibrilación auricular por internet. 1- 30 Oct 2009. London: St. Jude Medical; 2009. Disponible en: http://www.af-symposium.org/2009/lectures.php
12. García-Cosío F. ¿Hacia dónde se dirige la investigación sobre fibrilación auricular? Rev Esp Cardiol. 2000;53:1318-24.
13. Díaz M. ¿Cómo comenzar el tratamiento del paciente hipertenso? Rev Argent Cardiol. 2006 mayo-jun.74(3):191-3.
14. Celik T, Cagdas Yuksel U, Bugan B, Celik M, Fici F, Iyisoy A, et al. P-Wave dispersion and its relationship to aortic elasticity in young prehypertensive patients. Am J Hypertens. 2009;22(12):1270-5.
15. Moro Serrano C, Hernández-Madrid A. Fibrilación auricular: ¿estamos ante una epidemia? Rev Esp Cardiol. 2009;62:10-4.
Downloads
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
